Agents that recruit CD8+ T cells to the tumor milieu such as immunostimulants (i.e., cytokines) and DNA damaging agents that promote immunogenic cell death (such as chemotherapy), may alter the tumor microenvironment to favorably influence therapeutic responses and therefore new combination therapies are an area of clinical interest. Here, CD8A is linked to neoplasm.